About the Company
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK™ (oliceridine) injection, indicated inadults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new approach to treating a variety of CNS disorders.
Employees
25
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TRVN News
Trevena (TRVN) Price Target Decreased by 7.69% to 6.12
The average one-year price target for Trevena (NasdaqCM:TRVN) has been revised to 6.12 / share. This is an decrease of 7.69% ...
Trevena Ramps Up Efforts on TRV045, Turns Attention Away from OLINVYK Amid Challenging Hospital Environment
CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a leading pharmaceutical company, has recently unveiled its financial ...
Trevena Inc TRVN
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Trevena: Q4 Earnings Snapshot
CHESTERBROOK, Pa. (AP) — CHESTERBROOK, Pa. (AP) — Trevena Inc. (TRVN) on Monday reported a loss of $16.5 million in its fourth quarter. The Chesterbrook, Pennsylvania-based company said it had ...
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
CHESTERBROOK, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients ...
Loading the latest forecasts...